ClinicalTrials.gg
CompletedNCT02117687Updated Apr 18, 2019Results posted

A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye

A Phase 4 interventional study of carboxymethylcellulose 0.5%/glycerin 0.9% and sodium hyaluronate 0.18% in Dry Eye Syndromes and Keratoconjunctivitis Sicca, sponsored by Allergan. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-18.

Primary conditionKeratoconjunctivitis SiccaRegistry: Dry Eye SyndromesReclassifiedWhy we changed it
Registry
Dry Eye Syndromes — the first condition term the registry derived for this study.
ClinicalTrials.gg
Keratoconjunctivitis Sicca
Why
  1. The study's listed conditions name Keratoconjunctivitis Sicca, a narrower term within Dry Eye Syndromes.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate the safety and efficacy of OPTIVE FUSION™ compared to VISMED® Multi for the management of dry eye.

02

Conditions studied

  • Dry Eye Syndromes
  • Keratoconjunctivitis Sicca

Browse trials for

03

In context

Keratoconjunctivitis Sicca Reclassified

85 studies on the registry are indexed under Keratoconjunctivitis Sicca; 1 is open to participants now.

This study's enrollment of 80 is close to the median of 82 across 75 interventional studies indexed under Keratoconjunctivitis Sicca.

Browse Keratoconjunctivitis Sicca studies →

Lead sponsor

Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.

Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.

First submitted before Allergan became part of AbbVie.

Compared within Keratoconjunctivitis Sicca, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dry Eye Syndromes. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Use of artificial tears for dry eye in both eyes for at least 3 months
  • Use of preservative-free artificial tears at least twice daily for 2 weeks;

Exclusion criteria

Exclusion Criteria:

  • Cataract, laser-assisted in situ keratomileusis (LASIK), photorefractive keratectomy (PRK) surgery in the last 12 months
  • Use of punctal plugs or contact lenses in the last month
  • Active ocular allergy within last 2 years
  • Best corrected visual acuity (BCVA) less than 20/200 in either eye
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
80 participants (actual)

Study arms

  • Active comparator
    OPTIVE FUSION™

    1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.

    Drug: carboxymethylcellulose 0.5%/glycerin 0.9%

  • Active comparator
    VISMED® Multi

    1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.

    Drug: sodium hyaluronate 0.18%

Interventions

  • Drugcarboxymethylcellulose 0.5%/glycerin 0.9%

    Drug page: Carboxymethylcellulose

    1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.

    Also known as: OPTIVE FUSION™

  • 1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.

    Also known as: VISMED® Multi

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Global Ocular Staining Score in the Study Eye

    Global ocular staining of the study eye was graded from 0 to 15 and was the sum of corneal fluorescein staining severity, nasal conjunctiva lissamine green staining severity, and temporal conjunctiva lissamine green staining severity. Staining of the cornea followed ocular administration of fluorescein dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Staining of the conjunctiva followed ocular administration of lissamine green dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Conjunctival staining was evaluated in two zones, nasal and temporal.

    Time frame: Baseline, Day 35

Secondary outcomes

  1. Change From Baseline in Global Ocular Staining Score in the Study Eye

    Global ocular staining of the study eye was graded from 0 to 15 and was the sum of corneal fluorescein staining severity, nasal conjunctiva lissamine green staining severity, and temporal conjunctiva lissamine green staining severity. Staining of the cornea followed ocular administration of fluorescein dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Staining of the conjunctiva followed ocular administration of lissamine green dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Conjunctival staining was evaluated in two zones, nasal and temporal.

    Time frame: Baseline, Month 3

  2. Change From Baseline in Ocular Surface Disease Index© (OSDI) Score

    The OSDI is a 12-question survey for patients to document their dry eye disease symptoms on a 5-point scale (0=none of the time and 4=all of the time). Higher scores represent greater disability. Scores are totaled over the 12 questions and converted to a score of 0-100 (0=no disability and 100=complete disability). A negative number change from baseline represents an improvement and a positive number change from baseline represents a worsening.

    Time frame: Baseline, Day 35

  3. Change From Baseline in the Schirmer Test in the Study Eye

    The Schirmer's Test measures the rate of secretion of tears produced by the study eye over 5 minutes. The results indicate the presence of dry eye (Normal = greater than or equal to 10 millimeters (mm) of tears, Dry Eye = less than 10 mm of tears). The smaller the number, the more severe the dry eye. A positive number change from baseline indicates an increase in tears (improvement) and a negative number change from baseline indicates a decrease in tears (worsening).

    Time frame: Baseline, Day 35

  4. Subject Assessment of Dry Eye Symptoms on a 5-Point Scale

    Subjects assess dry eye symptoms on a 5-point scale (none, mild, moderate, severe, very severe).

    Time frame: Baseline, Day 35, Month 3

  5. Subject Global Assessment of Treatment Efficacy on a 5-Point Scale

    Subjects assess global treatment efficacy compared to baseline on a 5-point scale (much worse, worse, about the same, improved, much improved).

    Time frame: Baseline, Day 35, Month 3

  6. Subject Assessment of Treatment Acceptability on a 5-Point Scale

    Subjects assess treatment acceptability (likability and comfort) on a 5-point scale (strongly agree, agree, neither agree nor disagree, disagree, strongly disagree).

    Time frame: Day 35

  7. Investigator Global Assessment of Treatment Efficacy on a 4-Point Scale

    Investigators assess global treatment efficacy on a 4-point scale (very satisfactory, satisfactory, poor, very poor).

    Time frame: Day 35, Month 3

  8. Change From Baseline in Tear Break-up Time (TBUT) in the Study Eye

    TBUT is the time required for dry spots to appear on the surface of the eye after blinking in the worse eye. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film. A positive number change from baseline indicates an increase in TBUT (improvement) and a negative number change from baseline indicates a decrease in TBUT (worsening).

    Time frame: Baseline, Day 35

  9. Work Productivity and Activity Impairment Questionnaire Score

    The Work Productivity and Activity questionnaire assesses the effect of dry eye on the ability of subjects to work and perform regular activities on a scale from 0 to 10 during the past 7 days (0=dry eye had no effect on my work/daily activities to 10=dry eye completely prevented me from working/doing my daily activities). Since not all subjects were in full time employment during the study, not all items of the questionnaire were applicable to all subjects at each visit. Outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.

    Time frame: Baseline, Day 35, Month 3

  10. Change From Baseline in Corneal Staining in the Study Eye

    The cornea is the transparent front part of the eye which covers the iris and pupil. Staining of the cornea followed ocular administration of fluorescein dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). A negative number change from baseline represents a decrease in corneal staining (improvement) and a positive number change from baseline represents an increase in corneal staining (worsening).

    Time frame: Baseline, Day 35, Month 3

  11. Change From Baseline in Conjunctival Staining in the Study Eye

    The conjunctiva is the clear membrane covering the white surface of the eye. Staining of the conjunctiva followed ocular administration of lissamine green dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining) in the temporal and nasal locations. A negative number change from baseline represents a decrease in corneal staining (improvement) and a positive number change from baseline represents an increase in corneal staining (worsening).

    Time frame: Baseline, Day 35, Month 3

  12. Conjunctival Hyperaemia in the Study Eye

    Macroscopic conjunctival hyperemia (eye redness) is graded in the study eye on a 5-point scale (none, trace, mild, moderate, severe).

    Time frame: Baseline, Day 35, Month 3

  13. Study Product Use

    The number of times the study product is administered per day is recorded.

    Time frame: Day 8, Day 35, Month 3

07

Results

Posted Feb 19, 2016

Participant flow

Participant flow — Overall Study
MilestoneOPTIVE FUSION™VISMED® Multi
Started4040
Completed3936
Not completed14
Withdrew: Lost to follow-up01
Withdrew: Adverse event02
Withdrew: Other reasons11

Outcome measures

PrimaryChange From Baseline in Global Ocular Staining Score in the Study Eye

Global ocular staining of the study eye was graded from 0 to 15 and was the sum of corneal fluorescein staining severity, nasal conjunctiva lissamine green staining severity, and temporal conjunctiva lissamine green staining severity. Staining of the cornea followed ocular administration of fluorescein dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Staining of the conjunctiva followed ocular administration of lissamine green dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Conjunctival staining was evaluated in two zones, nasal and temporal.

Time frame:
Baseline, Day 35
Reported as:
Mean · Scores on a Scale
Change From Baseline in Global Ocular Staining Score in the Study Eye
Scores on a ScaleOPTIVE FUSION™VISMED® Multi
Baseline5.2 ± 1.115.2 ± 1.21
Change from Baseline at Day 35-1.5 ± 1.54-1.6 ± 1.54
SecondaryChange From Baseline in Global Ocular Staining Score in the Study Eye

Global ocular staining of the study eye was graded from 0 to 15 and was the sum of corneal fluorescein staining severity, nasal conjunctiva lissamine green staining severity, and temporal conjunctiva lissamine green staining severity. Staining of the cornea followed ocular administration of fluorescein dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Staining of the conjunctiva followed ocular administration of lissamine green dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Conjunctival staining was evaluated in two zones, nasal and temporal.

Time frame:
Baseline, Month 3
Reported as:
Mean · Scores on a Scale
Change From Baseline in Global Ocular Staining Score in the Study Eye
Scores on a ScaleOPTIVE FUSION™VISMED® Multi
Baseline5.2 ± 1.115.2 ± 1.21
Change from Baseline at Day 35-2.5 ± 2.23-2.4 ± 2.24
SecondaryChange From Baseline in Ocular Surface Disease Index© (OSDI) Score

The OSDI is a 12-question survey for patients to document their dry eye disease symptoms on a 5-point scale (0=none of the time and 4=all of the time). Higher scores represent greater disability. Scores are totaled over the 12 questions and converted to a score of 0-100 (0=no disability and 100=complete disability). A negative number change from baseline represents an improvement and a positive number change from baseline represents a worsening.

Time frame:
Baseline, Day 35
Reported as:
Mean · Scores on a Scale
Change From Baseline in Ocular Surface Disease Index© (OSDI) Score
Scores on a ScaleOPTIVE FUSION™VISMED® Multi
Baseline45.5 ± 22.0244.4 ± 17.60
Change from Baseline at Day 35-10.3 ± 13.51-12.9 ± 13.13
SecondaryChange From Baseline in the Schirmer Test in the Study Eye

The Schirmer's Test measures the rate of secretion of tears produced by the study eye over 5 minutes. The results indicate the presence of dry eye (Normal = greater than or equal to 10 millimeters (mm) of tears, Dry Eye = less than 10 mm of tears). The smaller the number, the more severe the dry eye. A positive number change from baseline indicates an increase in tears (improvement) and a negative number change from baseline indicates a decrease in tears (worsening).

Time frame:
Baseline, Day 35
Reported as:
Mean · Millimeters (mm)/5 Minutes
Change From Baseline in the Schirmer Test in the Study Eye
Millimeters (mm)/5 MinutesOPTIVE FUSION™VISMED® Multi
Baseline11.1 ± 10.228.7 ± 7.29
Change from Baseline at Day 350.1 ± 7.741.0 ± 5.44
SecondarySubject Assessment of Dry Eye Symptoms on a 5-Point Scale

Subjects assess dry eye symptoms on a 5-point scale (none, mild, moderate, severe, very severe).

Time frame:
Baseline, Day 35, Month 3
Reported as:
Number · Subjects
Subject Assessment of Dry Eye Symptoms on a 5-Point Scale
SubjectsOPTIVE FUSION™VISMED® Multi
Baseline Stinging/Burning - None (N=32,28)01
Baseline Stinging/Burning - Mild (N=32,28)74
Baseline Stinging/Burning - Moderate (N=32,28)1713
Baseline Stinging/Burning - Severe (N=32,28)79
Baseline Stinging/Burning - Very Severe (N=32,28)11
Day 35 Stinging/Burning - None52
Day 35 Stinging/Burning - Mild128
Day 35 Stinging/Burning - Moderate1717
Day 35 Stinging/Burning - Severe13
Day 35 Stinging/Burning - Very Severe01
Month 3 Stinging/Burning - None56
Month 3 Stinging/Burning - Mild145
Month 3 Stinging/Burning - Moderate1513
Month 3 Stinging/Burning - Severe16
Month 3 Stinging/Burning - Very Severe01
Baseline Itching - None (N=32,28)65
Baseline Itching - Mild (N=32,28)87
Baseline Itching - Moderate (N=32,28)121
Baseline Itching - Severe (N=32,28)63
Baseline Itching - Very Severe (N=32,28)02
Day 35 Itching- None108
Day 35 Itching- Mild87
Day 35 Itching- Moderate1513
Day 35 Itching- Severe22
Day 35 Itching- Very Severe01
Month 3 Itching- None1010
Month 3 Itching- Mild128
Month 3 Itching- Moderate119
Month 3 Itching- Severe23
Month 3 Itching- Very Severe01
Baseline Sandiness/Grittiness - None (N=32,28)21
Baseline Sandiness/Grittiness - Mild (N=32,28)65
Baseline Sandiness/Grittiness - Moderate (N=32,28)1912
Baseline Sandiness/Grittiness - Severe (N=32,28)58
Bsln Sandiness/Grittiness-Very Severe (N=32,28)02
Day 35 Sandiness/Grittiness - None74
Day 35 Sandiness/Grittiness - Mild138
Day 35 Sandiness/Grittiness - Moderate1413
Day 35 Sandiness/Grittiness - Severe14
Day 35 Sandiness/Grittiness - Very Severe02
Month 3 Sandiness/Grittiness - None78
Month 3 Sandiness/Grittiness - Mild174
Month 3 Sandiness/Grittiness - Moderate915
Month 3 Sandiness/Grittiness - Severe23
Month 3 Sandiness/Grittiness - Very Severe01
Baseline Blurred Vision - None (N=32,28)1110
Baseline Blurred Vision - Mild (N=32,28)87
Baseline Blurred Vision - Moderate (N=32,28)107
Baseline Blurred Vision - Severe (N=32,28)33
Baseline Blurred Vision - Very Severe (N=32,28)01
Day 35 Blurred Vision - None1613
Day 35 Blurred Vision - Mild109
Day 35 Blurred Vision - Moderate87
Day 35 Blurred Vision - Severe11
Day 35 Blurred Vision - Very Severe01
Month 3 Blurred Vision - None2014
Month 3 Blurred Vision - Mild79
Month 3 Blurred Vision - Moderate65
Month 3 Blurred Vision - Severe11
Month 3 Blurred Vision - Very Severe12
Baseline Dryness - None (N=32,28)11
Baseline Dryness - Mild (N=32,28)22
Baseline Dryness - Moderate (N=32,28)1310
Baseline Dryness - Severe (N=32,28)1312
Baseline Dryness - Very Severe (N=32,28)33
Day 35 Dryness - None43
Day 35 Dryness - Mild85
Day 35 Dryness - Moderate1614
Day 35 Dryness - Severe77
Day 35 Dryness - Very Severe02
Month 3 Dryness - None23
Month 3 Dryness - Mild125
Month 3 Dryness - Moderate1714
Month 3 Dryness - Severe46
Month 3 Dryness - Very Severe03
Baseline Light Sensitivity - None (N=32,28)12
Baseline Light Sensitivity - Mild (N=32,28)48
Baseline Light Sensitivity - Moderate (N=32,28)146
Baseline Light Sensitivity - Severe (N=32,28)97
Baseline Light Sensitivity - Very Severe (N=32,28)45
Day 35 Light Sensitivity - None52
Month 3 Light Sensitivity - Severe58
Month 3 Light Sensitivity - Very Severe13
Day 35 Light Sensitivity - Mild67
Day 35 Light Sensitivity - Moderate1811
Day 35 Light Sensitivity - Severe57
Day 35 Light Sensitivity - Very Severe14
Month 3 Light Sensitivity - None52
Month 3 Light Sensitivity - Mild1610
Month 3 Light Sensitivity - Moderate88
Baseline Painful or Sore - None (N=31,28)01
Baseline Painful or Sore - Mild (N=31,28)128
Baseline Painful or Sore - Moderate (N=31,28)1513
Baseline Painful or Sore - Severe (N=31,28)44
Baseline Painful or Sore - Very Severe (N=31,28)02
Day 35 Painful or Sore - None55
Day 35 Painful or Sore - Mild209
Day 35 Painful or Sore - Moderate913
Day 35 Painful or Sore - Severe12
Day 35 Painful or Sore - Very Severe02
Month 3 Painful or Sore - None59
Month 3 Painful or Sore - Mild173
Month 3 Painful or Sore - Moderate1016
Month 3 Painful or Sore - Severe22
Month 3 Painful or Sore - Very Severe (N=34,31)01
Baseline Other - None (N=3,1)00
Baseline Other - Mild (N=3,1)00
Baseline Other - Moderate (N=3,1)10
Baseline Other - Severe (N=3,1)00
Baseline Other - Very Severe (N=3,1)01
Day 35 Other - None (N=1,3)00
Day 35 Other - Mild (N=1,3)00
Day 35 Other - Moderate (N=1,3)11
Day 35 Other - Severe (N=1,3)01
Day 35 Other - Very Severe (N=1,3)01
Month 3 Other - None (N=1,3)01
Month 3 Other - Mild (N=1,3)00
Month 3 Other - Moderate (N=1,3)10
Month 3 Other - Severe (N=1,3)01
Month 3 Other - Very Severe (N=1,3)01
SecondarySubject Global Assessment of Treatment Efficacy on a 5-Point Scale

Subjects assess global treatment efficacy compared to baseline on a 5-point scale (much worse, worse, about the same, improved, much improved).

Time frame:
Baseline, Day 35, Month 3
Reported as:
Number · Subjects
Subject Global Assessment of Treatment Efficacy on a 5-Point Scale
SubjectsOPTIVE FUSION™VISMED® Multi
Day 35 - Much Worse00
Day 35 - Worse03
Day 35 - About the Same1211
Day 35 - Improved2114
Day 35 - Much Improved23
Month 3 - Much Worse01
Month 3 - Worse03
Month 3 - About the Same1110
Month 3 - Improved1913
Month 3 - Much Improved54
SecondarySubject Assessment of Treatment Acceptability on a 5-Point Scale

Subjects assess treatment acceptability (likability and comfort) on a 5-point scale (strongly agree, agree, neither agree nor disagree, disagree, strongly disagree).

Time frame:
Day 35
Reported as:
Number · Subjects
Subject Assessment of Treatment Acceptability on a 5-Point Scale
SubjectsOPTIVE FUSION™VISMED® Multi
Liked - Strongly Agree (N=35,30)148
Liked - Agree (N=35,30)1210
Liked - Neither Agree nor Disagree (N=35,30)69
Liked - Disagree (N=35,30)22
Liked - Strongly Disagree (N=35,30)11
Comfortable - Strongly Agree99
Comfortable - Agree1613
Comfortable - Neither Agree nor Disagree76
Comfortable - Disagree22
Comfortable - Strongly Disagree11
SecondaryInvestigator Global Assessment of Treatment Efficacy on a 4-Point Scale

Investigators assess global treatment efficacy on a 4-point scale (very satisfactory, satisfactory, poor, very poor).

Time frame:
Day 35, Month 3
Reported as:
Number · Subjects
Investigator Global Assessment of Treatment Efficacy on a 4-Point Scale
SubjectsOPTIVE FUSION™VISMED® Multi
Day 35 - Very Satisfactory138
Day 35 - Satisfactory1719
Day 35 - Poor54
Day 35 - Very Poor00
Month 3 - Very Satisfactory1510
Month 3 - Satisfactory1511
Month 3 - Poor59
Month 3 - Very Poor01
SecondaryChange From Baseline in Tear Break-up Time (TBUT) in the Study Eye

TBUT is the time required for dry spots to appear on the surface of the eye after blinking in the worse eye. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film. A positive number change from baseline indicates an increase in TBUT (improvement) and a negative number change from baseline indicates a decrease in TBUT (worsening).

Time frame:
Baseline, Day 35
Reported as:
Mean · Seconds
Change From Baseline in Tear Break-up Time (TBUT) in the Study Eye
SecondsOPTIVE FUSION™VISMED® Multi
Baseline5.52 ± 2.5755.75 ± 3.146
Change from Baseline at Day 350.6 ± 1.660.7 ± 2.00
SecondaryWork Productivity and Activity Impairment Questionnaire Score

The Work Productivity and Activity questionnaire assesses the effect of dry eye on the ability of subjects to work and perform regular activities on a scale from 0 to 10 during the past 7 days (0=dry eye had no effect on my work/daily activities to 10=dry eye completely prevented me from working/doing my daily activities). Since not all subjects were in full time employment during the study, not all items of the questionnaire were applicable to all subjects at each visit. Outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.

Time frame:
Baseline, Day 35, Month 3
Reported as:
Mean · Scores on a Scale
Work Productivity and Activity Impairment Questionnaire Score
Scores on a ScaleOPTIVE FUSION™VISMED® Multi
Baseline - Work Productivity (N=11,13)3.09 ± 1.9213.46 ± 3.382
Baseline - Activity Impairment3.91 ± 2.0354.35 ± 2.550
Day 35 - Work Productivity (N=11,9)2.55 ± 1.8092.33 ± 1.936
Day 35 - Activity Impairment (N=34,31)3.09 ± 2.0653.52 ± 2.393
Month 3 - Work Productivity (N=11,10)1.82 ± 0.9822.40 ± 2.066
Month 3 - Activity Impairment2.14 ± 1.6302.77 ± 2.232
SecondaryChange From Baseline in Corneal Staining in the Study Eye

The cornea is the transparent front part of the eye which covers the iris and pupil. Staining of the cornea followed ocular administration of fluorescein dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). A negative number change from baseline represents a decrease in corneal staining (improvement) and a positive number change from baseline represents an increase in corneal staining (worsening).

Time frame:
Baseline, Day 35, Month 3
Reported as:
Mean · Scores on a Scale
Change From Baseline in Corneal Staining in the Study Eye
Scores on a ScaleOPTIVE FUSION™VISMED® Multi
Baseline1.7 ± 0.681.9 ± 0.65
Change from Baseline at Day 35-0.4 ± 0.77-0.7 ± 0.83
Change from Baseline at Month 3-0.8 ± 0.84-0.9 ± 1.04
SecondaryChange From Baseline in Conjunctival Staining in the Study Eye

The conjunctiva is the clear membrane covering the white surface of the eye. Staining of the conjunctiva followed ocular administration of lissamine green dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining) in the temporal and nasal locations. A negative number change from baseline represents a decrease in corneal staining (improvement) and a positive number change from baseline represents an increase in corneal staining (worsening).

Time frame:
Baseline, Day 35, Month 3
Reported as:
Mean · Scores on a Scale
Change From Baseline in Conjunctival Staining in the Study Eye
Scores on a ScaleOPTIVE FUSION™VISMED® Multi
Baseline - Temporal1.7 ± 0.641.6 ± 0.81
Change from Baseline at Day 35 - Temporal-0.5 ± 0.66-0.5 ± 0.81
Change from Baseline at Month 3 - Temporal-0.8 ± 0.79-0.8 ± 0.92
Baseline - Nasal1.9 ± 0.661.7 ± 0.70
Change from Baseline at Day 35 - Nasal-0.6 ± 0.65-0.5 ± 0.68
Change from Baseline at Month 3 - Nasal-0.9 ± 0.97-0.7 ± 0.87
SecondaryConjunctival Hyperaemia in the Study Eye

Macroscopic conjunctival hyperemia (eye redness) is graded in the study eye on a 5-point scale (none, trace, mild, moderate, severe).

Time frame:
Baseline, Day 35, Month 3
Reported as:
Number · Subjects
Conjunctival Hyperaemia in the Study Eye
SubjectsOPTIVE FUSION™VISMED® Multi
Baseline - None88
Baseline - Trace1311
Baseline - Mild1310
Baseline - Moderate12
Baseline Severe00
Day 35 - None1712
Day 35 - Trace910
Day 35 - Mild98
Day 35 - Moderate01
Day 35 - Severe00
Month 3 - None2214
Month 3 - Trace87
Month 3 - Mild59
Month 3 - Moderate01
Month 3 - Severe00
SecondaryStudy Product Use

The number of times the study product is administered per day is recorded.

Time frame:
Day 8, Day 35, Month 3
Reported as:
Mean · Number of Times/Day
Study Product Use
Number of Times/DayOPTIVE FUSION™VISMED® Multi
Day 83.63 ± 1.1903.47 ± 0.900
Day 353.77 ± 1.2853.39 ± 0.761
Month 33.71 ± 1.1783.42 ± 0.958

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OPTIVE FUSION™—0/40 (0%)4/40 (10%)
VISMED® Multi—1/40 (2.5%)6/40 (15%)
Most frequent serious events
Most frequent serious events
EventOPTIVE FUSION™VISMED® Multi
PericarditisCardiac disorders0/401/40
Most frequent other events
Most frequent other events
EventOPTIVE FUSION™VISMED® Multi
Dry EyeEye disorders0/402/40
Eye DischargeEye disorders0/402/40
Eye IrritationEye disorders2/402/40
Eye PruritusEye disorders2/400/40

Baseline characteristics

Age, Customized
Age, Customized(Participants)OPTIVE FUSION™VISMED® MultiTotal
<65 years172542
≥65 years231538
Sex: Female, Male
Sex: Female, Male(Participants)OPTIVE FUSION™VISMED® MultiTotal
Female363369
Male4711
08

Study locations

2 sites
  • Paris, France
  • London, United Kingdom
09

References and documents

Publications

  • Labetoulle M, Chiambaretta F, Shirlaw A, Leaback R, Baudouin C. Osmoprotectants, carboxymethylcellulose and hyaluronic acid multi-ingredient eye drop: a randomised controlled trial in moderate to severe dry eye. Eye (Lond). 2017 Oct;31(10):1409-1416. doi: 10.1038/eye.2017.73. Epub 2017 Apr 28. Erratum In: Eye (Lond). 2017 Oct;31(10):1512. doi: 10.1038/eye.2017.124. PubMed 28452989 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2014 to primary completion in Jan 2015, 8 months.

Results were first posted in Feb 2016, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2014
First posted
Apr 21, 2014
StartActual
May 14, 2014
Primary completionActual
Jan 27, 2015
CompletionActual
Mar 17, 2015
Results first posted
Feb 19, 2016
Last update
Apr 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02117687
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Apr 21, 2014
Start date
May 14, 2014
Primary completion
Jan 27, 2015
Completion
Mar 17, 2015
Results posted
Feb 19, 2016
Last update
Apr 18, 2019

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carboxymethylcellulose · Hyaluronic Acid

Start the discussion